These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2987907)

  • 1. New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.
    Scheel-Krüger J; Arnt J
    Psychopharmacology Suppl; 1985; 2():46-57. PubMed ID: 2987907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of striato-nigral GABAergic pathway by chronic haloperidol treatment: the role of dopamine D1 receptor in the substantia nigra pars reticulata on the development of tardive dyskinesia.
    Shirakawa O; Maeda K; Sakai K
    Jpn J Psychiatry Neurol; 1993 Jun; 47(2):429-30. PubMed ID: 8271625
    [No Abstract]   [Full Text] [Related]  

  • 3. Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
    Cools AR
    Mod Probl Pharmacopsychiatry; 1983; 21():111-23. PubMed ID: 6140628
    [No Abstract]   [Full Text] [Related]  

  • 4. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GABA dysfunction in the pathophysiology of tardive dyskinesia.
    Tamminga CA; Thaker GK; Chase TN
    Psychopharmacology Suppl; 1985; 2():122-7. PubMed ID: 2987903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia and tardive dyskinesia: is schizophrenia also a "denervation hypersensitivity"?
    Kapit RM
    Med Hypotheses; 1977; 3(5):207-10. PubMed ID: 904502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man.
    Cools AR
    Clin Neurol Neurosurg; 1984; 86(3):178-95. PubMed ID: 6091966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiological mechanisms underlying tardive dyskinesia.
    Gerlach J
    Psychopharmacology Suppl; 1985; 2():98-103. PubMed ID: 2860666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Physiopathology and curative treatment of tardive dyskinesia].
    Wolf MA; Gautier J
    Encephale; 1987; 13(5):301-8. PubMed ID: 2892663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of tardive dyskinesia.
    Gunne LM; Häggström JE
    Psychopharmacology Suppl; 1985; 2():191-3. PubMed ID: 3858799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine hypothesis of schizophrenia revisited.
    van Kammen DP
    Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for an intrastriatal GABA control on motor activity arising from dopaminergic hyperfuction in the striatum.
    Scarnati E; Forchetti C; Ruggieri S; Agnoli A
    Acta Neurol (Napoli); 1978 Aug; 33(4):304-313. PubMed ID: 742442
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
    Gale K; Casu M
    Mol Cell Biochem; 1981 Sep; 39():369-405. PubMed ID: 6118827
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions between GABA, dopamine, acetylcholine, and glutamate-containing neurons in the extrapyramidal and limbic systems.
    Bartholini G; Scatton B; Worms P; Zivkovic B; Lloyd KG
    Adv Biochem Psychopharmacol; 1981; 30():119-28. PubMed ID: 6120626
    [No Abstract]   [Full Text] [Related]  

  • 15. GABA system: clinical research and treatment of tardive dyskinesia.
    Thaker GK; Hare TA; Tamminga CA
    Mod Probl Pharmacopsychiatry; 1983; 21():155-67. PubMed ID: 6419061
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopaminergic and GABAergic aspects of tardive dyskinesia [proceedings].
    Casey DE; Gerlach J; Magelund G; Christensen TR
    Psychopharmacol Bull; 1981 Jan; 17(1):49-50. PubMed ID: 7232658
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system.
    Scheel-Krüger J
    Acta Neurol Scand Suppl; 1986; 107():1-54. PubMed ID: 3014800
    [No Abstract]   [Full Text] [Related]  

  • 19. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
    Klawans HL; Goetz C; Nausieda PA; Weiner WJ
    Adv Exp Med Biol; 1977; 90():21-47. PubMed ID: 145167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.